Error message

EDS Server Issue
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): O'Malley, Stephanie S.. Yale University School of Medicine, New Haven, CT, US, O'Malley, Stephanie S.. Yale University School of Medicine, New Haven, CT, US, ; Krishnan-Sarin, Suchitra. Yale University School of Medicine, New Haven, CT, US; McKee, Sherry A.. Yale University School of Medicine, New Haven, CT, US; Leeman, Robert F.. Yale University School of Medicine, New Haven, CT, US; Cooney, Ned L., ORCID Cooney, Ned L., ORCID 0000-0001-6698-8312. Yale University School of Medicine, New Haven, CT, US; Meandzija, Boris. Yale University School of Medicine, New Haven, CT, US; Wu, Ran. Yale University School of Medicine, New Haven, CT, US; Makuch, Robert W.. Yale School of Public Health, New Haven, CT, US
  • Source:
    International Journal of Neuropsychopharmacology, Vol 12(5), Jun, 2009. pp. 589-597.
  • Publisher:
    United Kingdom : Cambridge University Press
  • Language:
    English
  • Document Type:
    Journal Article
  • Publication Type:
    Journal; Peer Reviewed Journal
  • Additional Information
    • Address:
      O'Malley, Stephanie S., Department of Psychiatry, Yale University School of Medicine, CMHC, SAC 202, 34 Park St, New Haven, CT, US, 06519, [email protected]
    • Source:
      Int J Neuropsychopharmacol
    • Physical Description:
      9
    • Other Publishers:
      United Kingdom : Oxford University Press
    • ISSN:
      1461-1457 (Print)
      1469-5111 (Electronic)
    • Keywords:
      dose dependent reduction, hazardous alcohol use, placebo controlled trial, naltrexone, smoking cessation
    • Abstract:
      The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking. At present, there are no published dose-ranging clinical trials of the oral preparation for treatment of problem drinking. The present study evaluated the effects of Ntx on alcohol use among the subset of hazardous drinkers (n = 102) who participated in a placebo-controlled, dose-ranging trial of oral Ntx (25-mg, 50-mg and 100-mg doses) combined with open-label transdermal nicotine patch for enhancing smoking cessation. On the primary outcome—no hazardous drinking (drinking that exceeded weekly or daily limits) during treatment—25 mg and 50 mg Ntx were superior to placebo (each p < 0.05). These findings remained after controlling for baseline predictors or smoking abstinence during treatment. Time to remission of hazardous drinking was examined as a secondary outcome with definitions of hazardous drinking based on weekly limits, daily limits and the combination of weekly and daily limits and the results were consistent with the primary findings. In conclusion, the findings suggest that Ntx can reduce the risk of hazardous drinking in smokers who are not seeking or receiving alcohol treatment, providing strong evidence for the pharmacological effects of Ntx on drinking. This effect appears to favour lower doses that may be better tolerated and less expensive than the higher 100-mg dose. Given its efficacy and favourable side-effect profile, the 25-mg dose should be considered for future studies of combination therapy. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
    • Subject Terms:
    • Subject Terms:
      Adult; Alcohol Drinking; Alcoholism; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naltrexone; Smoking; Smoking Cessation
    • PsycINFO Classification:
      Drug & Alcohol Rehabilitation (3383)
    • Population:
      Human
      Male
      Female
    • Location:
      US
    • Age Group:
      Adulthood (18 yrs & older)
    • Tests & Measures:
      Timeline Followback Interview
      Alcohol Use Disorders Identification Test   DOI: 10.1037/t01528-000
      Center for Epidemiologic Studies Depression Scale
      Fagerstrom Test for Nicotine Dependence
    • Grant Sponsorship:
      Sponsor: National Institutes of Health, US
      Grant Number: P50-DA-13334; P50-AA-15632; K02-AA00171; R01-AA11197
      Recipients: No recipient indicated

      Sponsor: Robert Wood Johnson Foundation, US
      Grant Number: 039787
      Recipients: No recipient indicated

      Sponsor: US Department of Veterans Affairs, US
      Recipients: No recipient indicated

      Sponsor: GlaxoSmithKline
      Other Details: Generously donated nicotine patches
      Recipients: No recipient indicated
    • Methodology:
      Empirical Study; Quantitative Study; Treatment Outcome
    • Physical Description:
      Print
    • Publication Date:
      First Posted: Sep 17, 2008; Accepted: Jul 31, 2008; Revised: Jul 28, 2008; First Submitted: May 1, 2008
    • Publication Date:
      20100201
    • Publication Date:
      20160502
    • Copyright:
      CINP. 2008
    • Accession Number:
      http://dx.doi.org/10.1017/S146114570800936X
    • Accession Number:
      18796184
    • Accession Number:
      2009-09326-002
    • Number of Citations in Source:
      31
  • Citations
    • ABNT:
      O’MALLEY, S. S. et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, [s. l.], v. 12, n. 5, p. 589–597, 2009. DOI 10.1017/S146114570800936X. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=psyh&AN=2009-09326-002. Acesso em: 22 out. 2020.
    • AMA:
      O’Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology. 2009;12(5):589-597. doi:10.1017/S146114570800936X
    • APA:
      O’Malley, S. S., Krishnan-Sarin, S., McKee, S. A., Leeman, R. F., Cooney, N. L., Meandzija, B., Wu, R., & Makuch, R. W. (2009). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, 12(5), 589–597. https://doi.org/10.1017/S146114570800936X
    • Chicago/Turabian: Author-Date:
      O’Malley, Stephanie S., Suchitra Krishnan-Sarin, Sherry A. McKee, Robert F. Leeman, Ned L. Cooney, Boris Meandzija, Ran Wu, and Robert W. Makuch. 2009. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12 (5): 589–97. doi:10.1017/S146114570800936X.
    • Harvard:
      O’Malley, S. S. et al. (2009) ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, 12(5), pp. 589–597. doi: 10.1017/S146114570800936X.
    • Harvard: Australian:
      O’Malley, SS, Krishnan-Sarin, S, McKee, SA, Leeman, RF, Cooney, NL, Meandzija, B, Wu, R & Makuch, RW 2009, ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, International Journal of Neuropsychopharmacology, vol. 12, no. 5, pp. 589–597, viewed 22 October 2020, .
    • MLA:
      O’Malley, Stephanie S., et al. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology, vol. 12, no. 5, June 2009, pp. 589–597. EBSCOhost, doi:10.1017/S146114570800936X.
    • Chicago/Turabian: Humanities:
      O’Malley, Stephanie S., Suchitra Krishnan-Sarin, Sherry A. McKee, Robert F. Leeman, Ned L. Cooney, Boris Meandzija, Ran Wu, and Robert W. Makuch. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” International Journal of Neuropsychopharmacology 12, no. 5 (June 2009): 589–97. doi:10.1017/S146114570800936X.
    • Vancouver/ICMJE:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology [Internet]. 2009 Jun [cited 2020 Oct 22];12(5):589–97. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=psyh&AN=2009-09326-002